• Chimeric Therapeutics is trading 45.71% down today at A$0.02 after announcing its intention to enter negotiations with its creditors.
  • Trading resumed on August 19, 2026, following a halt that preceded this significant company update, which appears to have triggered the sharp selloff.
  • This development of creditor negotiations serves as a major catalyst for the stock's performance.